Unknown OBSERVATIONAL NCT05661266

Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis

Sponsor: Innodem Neurosciences

Updated 5 times since 2023 Last updated: Oct 17, 2023 Started: Aug 16, 2023 Primary completion: Apr 30, 2025 Completion: Apr 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05661266, this observational or N/A phase trial focuses on Multiple Sclerosis and remains ongoing. Sponsored by Innodem Neurosciences, it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Dec 2025 — Present [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Dec 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Nov 2023 — Jul 2024 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Jan 2023 — Nov 2023 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Innodem Neurosciences

Data source: Innodem Neurosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada